The UK contract research organisation (CRO) made the comments at the Society of Toxicology (SOT) annual meeting in San Diego, US last week, telling us developments in invitro testing and strategies for exposure and risk assessment as areas of activity.
“Those topics are important to our customer base and our scientists are participating in several sessions as part of our ongoing efforts to share insights and stay abreast of the latest advances in science and technology impacting developmental research.”
Huntingdon – which is due to rebrand this year to mark the integration of recent acquisition Harlan Life Sciences – also presented at SOT on topics ranging from drug safety assessment to testing of chemicals and crop protection agents.
Here comes the science
A Huntingdon spokesman added “we are also tapping into some of the hot topics of this meeting, such as the use of in vitro methods in compound development, one of our posters discusses the regulatory drivers of in vitro alternatives for the testing of cosmetics.”
Regulators worldwide have been working to reduce the cosmetics industry’s use of animals for safety testing for many years.
In drug development animal testing is mandatory.
However, that does not mean alternatives are not being sought according to fellow SOT attendee PETA, which was also at the conference this year to present on efforts to develop in vitro replacements.
Amy Clippinger, a scientific advisor for the animal rights group, told us the meeting “gives us a forum to make sure we stay on top of the most cutting edge approaches that some companies are developing to replace, reduce or refine the use of animals in experiments.”
“We present our own original research and information on the work we do to ensure that these strategies to minimize animal use are approved for use by the appropriate agencies, and also that they are put into use as widely as possible once they’ve been approved.”